title: Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer.
abstract: OBJECTIVE
  To investigate the potential of low-dose cyclophosphamide (LD-CTX) and anti-CD25 antibody to prevent activation of regulatory T cells (Tregs) during radiation therapy.
  
  
  METHODS
  We used LD-CTX and anti-CD25 monoclonal antibody as a means to inhibit Tregs and improve the therapeutic effect of radiation in a mouse model of lung and colon cancer. Mice were irradiated on the tumor mass of the right leg and treated with LD-CTX and anti-CD25 antibody once per week for 3 weeks.
  
  
  RESULTS
  Combined treatment of LD-CTX or anti-CD25 antibody with radiation significantly decreased Tregs in the spleen and tumor compared with control and irradiation only in both lung and colon cancer. Combinatorial treatments resulted in a significant increase in the effector T cells, longer survival rate, and suppressed irradiated and distal nonirradiated tumor growth. Specifically, the combinatorial treatment of LD-CTX with radiation resulted in outstanding regression of local and distant tumors in colon cancer, and almost all mice in this group survived until the end of the study.
  
  
  CONCLUSIONS
  Our results suggest that Treg depletion strategies may enhance radiation-mediated antitumor immunity and further improve outcomes after radiation therapy.
authors.affiliation: Dongnam Institute of Radiological and Medical Sciences, Busan, Korea; Department of Biochemistry, Pusan National University School of Medicine, Yangsan, Korea.
authors.forename: Cheol-Hun
authors.initials: CH
authors.lastname: Son
authors.affiliation: Department of Biochemistry, Pusan National University School of Medicine, Yangsan, Korea.
authors.forename: Jae-Ho
authors.initials: JH
authors.lastname: Bae
authors.affiliation: Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
authors.forename: Dong-Yeok
authors.initials: DY
authors.lastname: Shin
authors.affiliation: Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
authors.forename: Hong-Rae
authors.initials: HR
authors.lastname: Lee
authors.affiliation: Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
authors.forename: Wol-Soon
authors.initials: WS
authors.lastname: Jo
authors.affiliation: Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
authors.forename: Kwangmo
authors.initials: K
authors.lastname: Yang
authors.affiliation: Dongnam Institute of Radiological and Medical Sciences, Busan, Korea. Electronic address: biotek01@hanmail.net.
authors.forename: You-Soo
authors.initials: YS
authors.lastname: Park
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D053645:Interleukin-2 Receptor alpha Subunit / Q000037:antagonists & inhibitors*; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000528:radiation effects*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D003520:Cyclophosphamide